Patents by Inventor Brij B. Saxena

Brij B. Saxena has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8088757
    Abstract: The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a betulinol derivative compound of Formula (I). Also disclosed are conjugated and immunoconjugated derivatives of the compound of Formula (I) as well as methods of making and using them.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: January 3, 2012
    Assignee: BioRings LLC
    Inventors: Brij B. Saxena, Premila Rathnam
  • Patent number: 8008280
    Abstract: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: August 30, 2011
    Assignee: Biorings LLC
    Inventors: Brij B. Saxena, Premila Rathnam
  • Publication number: 20090246254
    Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 1, 2009
    Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
  • Patent number: 7563612
    Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: July 21, 2009
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Brij B. Saxena, Premila Rathnam, Makul Singh, Meirong Hao
  • Publication number: 20090176753
    Abstract: The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a betulinol derivative compound of Formula (I). Also disclosed are conjugated and immunoconjugated derivatives of the compound of Formula (I) as well as methods of making and using them.
    Type: Application
    Filed: September 12, 2005
    Publication date: July 9, 2009
    Inventors: Brij B. Saxena, Premila Rathnam
  • Patent number: 7521064
    Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: April 21, 2009
    Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
  • Patent number: 7488594
    Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: February 10, 2009
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Brij B. Saxena, Premila Rathnam, Mukul Singh, Meirong Hao
  • Publication number: 20080286291
    Abstract: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.
    Type: Application
    Filed: September 12, 2005
    Publication date: November 20, 2008
    Inventors: Brij B. Saxena, Premila Rathnam
  • Patent number: 6890533
    Abstract: The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: and HO-antibody-spacer-(A2)n and, in particular, betulinol dimethyl ether. Methods for making and using these derivatives and conjugates, as well as a method for making and using betulonic aldehyde, are also disclosed.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: May 10, 2005
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Arkadiy L. Bomshteyn, Premila Rathnam, Brij B. Saxena
  • Patent number: 6723556
    Abstract: Purified hCG-hLH receptor, hCG-hLH receptor-hCG complex and combinations between their subunits as antigens, as well as antibodies thereto which are useful as a contraceptive vaccine. Antibodies to LH-R are useful in regulating steroid hormone production. Nucleic acid sequences encoding polypeptides with LH receptor activity were obtained and sequenced.
    Type: Grant
    Filed: September 14, 1993
    Date of Patent: April 20, 2004
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Brij B. Saxena, Premila Rathnam
  • Publication number: 20040013730
    Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.
    Type: Application
    Filed: July 31, 2003
    Publication date: January 22, 2004
    Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
  • Publication number: 20040001837
    Abstract: The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: 1
    Type: Application
    Filed: June 3, 1998
    Publication date: January 1, 2004
    Inventors: ARKADIY L. BOMSHTEYN, PREMILA RATHNAM, BRIJ B. SAXENA
  • Publication number: 20030036540
    Abstract: The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: 1
    Type: Application
    Filed: August 2, 2002
    Publication date: February 20, 2003
    Inventors: Arkadiy L. Bomshteyn, Premila Rathnam, Brij B. Saxena
  • Patent number: 4966888
    Abstract: Purified hCG-hLH receptor, hCG-hLH receptor-hCG complex and combinations between their subunits as antigens, as well as antibodies thereto which are useful as a contraceptive vaccine.
    Type: Grant
    Filed: September 23, 1986
    Date of Patent: October 30, 1990
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Brij B. Saxena, Premila Rathnam, Mukul Singh
  • Patent number: 4880914
    Abstract: A method to obtain a substantially pure and stable hLH-hCG receptor from gonadal cells is disclosed. The characteristics of the purified receptor are disclosed. The receptor, in addition to being used as receptor in an enzyme- or dye-receptor assay for hLH and/or hCG, can be used to purify hLH or hCG used in the preparation of standard dye-hormone or enzyme-hormone complexes. These complexes can be used in enzyme- or dye-immunoassays, as well as the receptor assay.
    Type: Grant
    Filed: September 23, 1985
    Date of Patent: November 14, 1989
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Brij B. Saxena, Premila Rathnam
  • Patent number: 4693969
    Abstract: A reagent for use in a "sandwich" enzyme-immunoassay comprising a polymer of a bioactive substance-specific antibody:enzyme conjugate, wherein said antibody is conjugated to said enzyme by means of heterobifunctional cross-linking agent and a "sandwich" enzyme-immunoassay employing the polymer.
    Type: Grant
    Filed: May 4, 1984
    Date of Patent: September 15, 1987
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Brij B. Saxena, Premila Rathnam
  • Patent number: 4560649
    Abstract: A method to obtain a substantially pure and stable hLH-hCG receptor from gonadal cells is disclosed. The characteristics of the purified receptor are disclosed. The receptor, in addition to being used as receptor in an enzyme- or dye-receptor assay for hLH and/or hCG, can be used to purify hLH or hCG used in the preparation of standard dye-hormone or enzyme-hormone complexes. These complexes can be used in enzyme- or dye-immunoassays, as well as the receptor assay.
    Type: Grant
    Filed: November 9, 1982
    Date of Patent: December 24, 1985
    Assignee: Cornell Research Foundation
    Inventors: Brij B. Saxena, Premila Rathnam
  • Patent number: 4094963
    Abstract: Disclosed is a method for the determination of the hormone human chorionic gonadotropin (HCG), luteinizing hormone (LH), prolactin (PRL) and HCG-like material in an aqueous sample comprising contacting a highly specific receptor for these hormones with an aqueous sample to be tested, providing a means of indicating whether binding has taken place between the receptor and hormone possibly contained the sample and observing the indicating means to determine the presence of the hormone in the sample. PRL may be determined separately or simultaneously with the HCG and LH. The receptor is a plasma membrane extract from the corpus luteum of an animal which possesses the receptor for HCG, LH, PRL and HCG-like material. Radioassay indicating means are preferred, according to which competitive protein binding between radioisotopically labeled hormone and hormone present in the sample is radiologically determined. The method has particular application to the determination to pregnancy in the human female.
    Type: Grant
    Filed: May 20, 1976
    Date of Patent: June 13, 1978
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Brij B. Saxena
  • Patent number: 4016250
    Abstract: Method for the determination of the hormone human chorionic gonadotropin (HCG), luteinizing hormone (LH), prolactin (PRL) and HCG-like material in an aqueous sample comprising contacting a highly specific receptor for these hormones with an aqueous sample to be tested, providing a means of indicating whether binding has taken place between the receptor and hormone possibly contained in the sample and observing the indicating means to determine the presence of the hormone in the sample. PRL may be determined separately or simultaneously with the HCG and LH. The receptor is a plasma membrane extract from the corpus luteum of an animal which possesses the receptor for HCG, LH, PRL and HCG-like material. Radioassay indicating means are preferred, according to which competitive protein binding between radioisotopically labeled hormone and hormone present in the sample is radiologically determined. The method has particular application to the determination to pregnancy in the human female.
    Type: Grant
    Filed: November 11, 1974
    Date of Patent: April 5, 1977
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Brij B. Saxena